New Zealand markets closed

NeuroMetrix, Inc. (NURO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.6100-0.0900 (-2.43%)
At close: 04:00PM EDT
3.8000 +0.19 (+5.26%)
After hours: 05:29PM EDT
Full screen
Loading interactive chart…
  • GlobeNewswire

    NeuroMetrix Reports that Quell® Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia

    WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced U.S. Food and Drug Administration (FDA) De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity. The Company received FDA Breakthrough Designation for the use of Quell to treat fibromyalgia in July 2021. Fibromyalgia is a chronic condition characterized by generalized pain, fatigue, poor sleep, memory an

  • GlobeNewswire

    NeuroMetrix Reports Q1 2022 Financial Results

    WOBURN, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2022. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices. Highlights: Q1 2022 revenue of $2.3 million increased by 6.8% from $2.2 million in the prior year. DPNCheck® sales into Medicare Advantage were the pr

  • GlobeNewswire

    NeuroMetrix, Inc. Announces Date for First Quarter 2022 Financial Results Conference Call

    WOBURN, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 first quarter financial results before the opening of the market on April 26, 2022. The Company will host a conference call at 8:00 a.m., Eastern Time on April 26, 2022 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation cod